Max Jacobs

Dr. Max Jacobs

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Blood
Verified
Journal Article
Closed access
JRJoseph M. Rocco
Joseph M. Rocco
JOJoseph H. Oved
Joseph H. Oved
RPRikita J. Patel
Rikita J. Patel
AHA. Zara Herskovits
A. Zara Herskovits
NNNamitha Nair
Namitha Nair
WJWilliam T. Johnson
William T. Johnson
Hemophagocytic lymphohistiocytosis (HLH) is an interferon gamma–driven hyperinflammatory syndrome with high morbidity and mortality. Identifying reliable prognostic biomarkers is challenging due to various predisposing conditions and triggers. C-X-C-motif ligand 9 (CXCL9) is a clinically validated biomarker and surrogate marker of interferon gamma–mediated inflammation. We aimed to identify the role of CXCL9 in predicting severe disease and death in adults with HLH using a multicenter retrospective cohort of consecutively hospitalized patients who underwent a clinical evaluation for HLH that included CXCL9 testing. Patients were classified as HLH if they met HLH-2004 and/or HScore criteria. Conditional inference decision trees and Cox regression models were used to identify which clinical variables associated with acute mortality in patients with HLH. Overall, 171 patients were reviewed, and 126 patients met HLH criteria. The median age was 55 years (interquartile range, 40-66), with 62% male and 51% White. CXCL9 was markedly elevated in patients with HLH. Unbiased decision tree modeling, incorporating all clinical laboratory values, identified only CXCL9 of >16 100 pg/mL as the optimal predictor of inpatient mortality. Cox regression models demonstrated that CXCL9 of >16 100 pg/mL was significantly associated with 90-day mortality when controlling for important covariates. This shorter time to death in the elevated CXCL9 subgroup remained significant even after subdividing patients into those with malignancy (n = 53) and nonmalignancy HLH (n = 73). Continuous increases in CXCL9 within the cohort strongly associated with greater mortality. CXCL9 is a novel clinical marker that identifies high-risk HLH independent of underlying disease and could be used to select patients for early and aggressive targeted immunomodulatory therapy.

2 November 2022 in Life
Verified
Journal Article
Open access
PDF file
ANAdeel Nasrullah
Adeel Nasrullah
SVShiza Virk
Shiza Virk
ASAaisha Shah
Aaisha Shah
MJMax Jacobs
Max Jacobs
AHAmina Hamza
Amina Hamza
SSSwathi Sangli
Swathi Sangli
The Coronavirus disease (COVID-19) pandemic of 2019 has resulted in significant morbidity and mortality, especially from severe acute respiratory distress syndrome (ARDS). As of September 2022, more than 6.5 million patients have died globally, and up to 5% required intensive care unit treatment. COVID-19-associated ARDS (CARDS) differs from the typical ARDS due to distinct pathology involving the pulmonary vasculature endothelium, resulting in diffuse thrombi in the pulmonary circulation and impaired gas exchange. The National Institute of Health and the Society of Critical Care Medicine recommend lung-protective ventilation, prone ventilation, and neuromuscular blockade as needed. Further, a trial of pulmonary vasodilators is suggested for those who develop refractory hypoxemia. A review of the prior literature on inhaled pulmonary vasodilators in ARDS suggests only a transient improvement in oxygenation, with no mortality benefit. This narrative review aims to highlight the fundamental principles in ARDS management, delineate the fundamental differences between CARDS and ARDS, and describe the comprehensive use of inhaled pulmonary vasodilators. In addition, with the differing pathophysiology of CARDS from the typical ARDS, we sought to evaluate the current evidence regarding the use of inhaled pulmonary vasodilators in CARDS.

8 September 2023 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
MJMax Jacobs
Max Jacobs
DBDerek N. Bremmer
Derek N. Bremmer
NSNathan R. Shively
Nathan R. Shively
MMMatthew Moffa
Matthew Moffa
TTTamara L. Trienski
Tamara L. Trienski
TWThomas L. Walsh
Thomas L. Walsh
Objective:To assess the safety and efficacy of a novel beta-lactam allergy assessment algorithm managed by an antimicrobial stewardship program (ASP) team.Design:Retrospective analysis.Setting:One quaternary referral teaching hospital and one tertiary care teaching hospital in a large western Pennsylvania health network.Patients or participants:Patients who received a beta-lactam challenge dose under the beta-lactam allergy assessment algorithm.Interventions:A beta-lactam allergy assessment protocol was designed and implemented by an ASP team. The protocol risk stratified patients’ reported allergies to identify patients appropriate for a challenge with a beta-lactam antibiotic. This retrospective analysis assessed the safety and efficacy of this protocol among patients receiving a challenge dose from November 2017 to July 2021.Results:Over a 45-month period, 119 total patients with either penicillin or cephalosporin allergies entered the protocol. Following a challenge dose, 106 (89.1%) patients were treated with a beta-lactam. Eleven patients had adverse reactions to a challenge dose, one of which required escalation of care to the intensive care unit. Of the patients with an unknown or low-risk reported allergy, 7/66 (10.6%) had an observed adverse reaction compared to 3/42 (7.1%) who had an observed reaction with a reported high-risk or anaphylactic allergy.Conclusions:Our implemented protocol was safe and effective, with over 90% of patients tolerating the challenge without incident and many going on to receive indicated beta-lactam therapy. This protocol may serve as a framework for other inpatient ASP teams to implement a low-barrier allergy assessment led by ASP teams.

9 May 2024 in Hematology Reports
Verified
Journal Article
Open access
PDF file
AAAbraham Attah
Abraham Attah
CPChelsea Peterson
Chelsea Peterson
MJMax Jacobs
Max Jacobs
RBRama Bhagavatula
Rama Bhagavatula
DSDeep Shah
Deep Shah
YSYazan Samhouri
Yazan Samhouri
Heparin products are frequently used in the inpatient setting to prevent and treat venous thromboembolism, but they simultaneously put patients at risk of developing heparin-induced thrombocytopenia (HIT). The 4Ts score determines the pretest probability of HIT. Diagnosis is made with a screening antiplatelet factor (PF4) immunoassay and the serotonin-release assay (SRA) as a confirmatory test. Anti-PF4 assays have high sensitivity (98%) but lower specificity (50%) and result in frequent false-positive tests. We present a rare case from our institution of a patient with anti-PF4–Polyanion ELISA-negative, SRA-positive HIT and describe the challenges in making a timely diagnosis in this case.

28 January 2025 in IDCases
Verified
Journal Article
Open access
MJMax Jacobs
Max Jacobs
JRJoseph M. Rocco
Joseph M. Rocco
LALisa K. Andersen
Lisa K. Andersen
TRThomas E. Robertson
Thomas E. Robertson
The incidence of babesiosis is increasing and clinicians should have a high index of suspicion due to its diagnostic challenges and variable disease course, from asymptomatic infection to fulminant disease. We present a case of fatal secondary hemophagocytic lymphohistiocytosis (sHLH) due to acute babesiosis in a previously healthy adult. We also present a comprehensive review of previously reported sHLH cases triggered by babesiosis. Host factors, such as immunocompromising conditions or medications, appear to be a risk factor for developing sHLH while it is unclear if percent parasitemia of babesia correlates with development or outcomes of HLH. Increasing awareness to improve time to diagnosis is vital for treating both babesiosis and sHLH, while future studies should investigate the role for immunomodulator therapy in this setting.

31 July 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ASAnindya Samanta
Anindya Samanta
JMJames Miller
James Miller
MJMax Jacobs
Max Jacobs
SBShikha Bhatia
Shikha Bhatia
PNPatricia Nelson
Patricia Nelson